QUOTE AND NEWS
GenEng News  May 14  Comment 
Immunotherapy enables a patient’s own immune system to battle cancerous target cells instead of either attacking the target cells directly or using whole-body approaches. Programmed death receptor-1 (PD-1), expressed on cell types including T...
GenEng News  May 14  Comment 
From small molecule and fragment-library screening to antibody-antigen target specificity, ligand screening is an increasingly important part of the drug discovery process. Ligand screening allows researchers to determine protein binding...
newratings.com  May 14  Comment 
PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) announced the presentation of further data from its chronic migraine phase 2b study evaluating the efficacy and safety, versus placebo, of two doses of TEV-48125, an...
GenEng News  May 11  Comment 
Ligand Pharmaceuticals said today it acquired rights to more than 15 biologic development programs—along with their potential future milestone payments and royalties—from Selexis for $4 million cash. The agreement is based on more than 15...
newratings.com  May 11  Comment 
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) reported that first-quarter net income declined to $0.75 million or $0.04 per share from $2.10 million or $0.10 per share in the prior-year quarter. Excluding items, adjusted net income...
Benzinga  May 5  Comment 
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Viking Therapeutics, Inc. (NASDAQ: VKTX) announced that it had closed its initial public offering (the "Viking IPO") of 3,000,000 shares of its common stock at an initial offering price to...
newratings.com  Apr 29  Comment 
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) partner Viking Therapeutics Inc. (VKTX) announced that it has priced its initial public offering of 3 million shares of its common stock at an initial offering price to the public of $8.00...
FierceBiotech  Apr 22  Comment 
Ronald Evans, the heavyweight Salk Institute researcher and serial entrepreneur who co-founded Ligand Pharmaceuticals, Syndax, and X-Ceptor, is putting his shoulder behind a new stealth biotech in San Diego named Metacrine.





You may also be interested in articles related to Ligand Pharmaceuticals (LGND):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki